Flexion tout headline results from osteoarthritis study; Savara bumps B round to $14M;

@FierceBiotech: Where were the breakthrough drugs for diabetes at ADA 2013? Editor's corner | Follow @FierceBiotech

 @JohnCFierce: Have to wonder how PTC's IPO will come out as questions are raised about its lead obsession, um, program. Article | Follow @JohnCFierce

@RyanMFierce: Verastem launching a PhI for second FAK inhibitor in pipeline. | Follow @RyanMFierce

 @EmilyMFierce: And back to biotech... Genetic biomarkers could help tailor breast cancer therapies. Article | Follow @EmilyMFierce

> Flexion Therapeutics says its Phase IIb study for FX006, its lead compound, delivered a statistically significant improvement over a standard therapy for pain relief among osteoarthritis patients. There was no Phase IIb data in the release, which focused on top-line results. "Immediate release steroids are currently front-line intra-articular therapy for patients with degenerative conditions of the knee," said Matt Provencher, chief of the sports medicine service at Massachusetts General Hospital. "With the magnitude and durability of both pain relief and improvement in function seen in this trial, FX006 has the potential to become the new front-line standard-of-care for patients with knee osteoarthritis. Company executives were not available for comment. Release

> Austin-based Savara has reportedly bumped its Series B round to $14.3 million with the help of a host of investors. The biotech is studying an inhaled antibiotic for cystic fibrosis patients. Story

> Navidea Biopharmaceuticals has closed on $25 million in debt financing led by GE Capital. Release

Medical Device News

@FierceMedDev: Activaero readies for hoped-for EU launch of its first drug/device treatment. Editor's corner | Follow @FierceMedDev

@DamianFierce: Delcath is axing 20% of its workforce after the FDA frowned upon its cancer-treating device. News | Follow @DamianFierce

> Thermo pours $9.5M into Chinese R&D shop. More

> Navidea raises $25M to market Lymphoseek. Item

> Intuitive hit with FDA warning over da Vinci reports. Story

> NanoString craves $54M in scaled-back IPO. Report

Pharma News

@FiercePharma: U.K. cost agency recommends Bayer's Xarelto to prevent potentially fatal blood clots in the lungs and legs. More | Follow @FiercePharma

@EricPFierce: Ranbaxy gets some support from India's Supreme Court as company faces down concerns there. Item | Follow @EricPFierce

@CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Report | Follow @CarlyHFierce

> Novartis says asthma blockbuster Xolair also effective against serious hives. Article

> Spain sugarcoats pharma-purchasing medicine with payment guarantee. Story

> Sanofi, Novartis, GlaxoSmithKline reportedly circling India's Elder Pharma. More

Biomarkers News

> Arizona's TGen and Ventana Medical Systems partner to find cancer biomarkers. News

> New diagnostic IDs patients unlikely to benefit from chemoradiation. Item

> Traumatic brain injury biomarker company raises $6M for diagnostic. Item

> HPV antibodies point researchers to high risk for oral cancer. Story

> Brain scan may provide biomarker guideposts to ideal depression treatment. Article

Drug Delivery News

@MichaelGFierce: Trending right now at FierceDrugDelivery: Insulin delivery devices at ADA 2013. Roundup | Follow @MichaelGFierce

> Acorda reports positive data for epilepsy nasal spray. Item

> Alnylam posts positive preclinical RNAi delivery results for fatal conditions. Article

> Microbubbles for imaging offer targeted drug-delivery approach. More

> Peptide-coated nano-gold shows cancer-fighting promise. Report

And Finally... A new study points to a sharp increase in the number of children being hospitalized for inflammatory bowel disease. Release